Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocytosis and Clonal Hematopoiesis in Peripheral Blood as Indicators of Myeloid Neoplasm in Erdheim-Chester Disease.

Clinical laboratory·2026
Same author

Clinico-Pathologic Features of Adult Erdheim-Chester Disease in South Korea: A Multicenter Retrospective Study (KCSG LY22-15).

Cancer research and treatment·2026
Same author

Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma.

Blood cancer journal·2026
Same author

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Blood·2026
Same author

Structural, Compositional, and Dielectric State Profiling in Label-Free Single-Cell Monitoring.

Small methods·2026
Same author

Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910).

Cancer research and treatment·2026

Related Experiment Video

Updated: May 25, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma.

Kyung Ju Ryu1, Haein Ji1, Bon Park1

  • 1Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, 81 Irwon-ro Gangnam-gu, Seoul, 06351, Korea.

Scientific Reports
|February 25, 2025
PubMed
Summary
This summary is machine-generated.

MicroRNAs miR-340-5p and miR-424-5p regulate PD-L1 in Extranodal NK/T-cell lymphoma (ENKTL). Low serum miR-340-5p predicts poor response to pembrolizumab immunotherapy in ENKTL patients.

Keywords:
BiomarkersNK/T-cell LymphomaPD-L1miR-340-5p

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Related Experiment Videos

Last Updated: May 25, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.5K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Extranodal NK/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis.
  • Elevated PD-L1 expression is linked to chemoresistance and poor outcomes in ENKTL.
  • Understanding PD-L1 regulation is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) in regulating PD-L1 expression in ENKTL.
  • To identify novel therapeutic targets and predictive biomarkers for pembrolizumab response.
  • To explore the potential of miR-340-5p and miR-424-5p in ENKTL treatment strategies.

Main Methods:

  • miRNA sequencing and functional assays were performed on ENKTL cells.
  • Ribonucleoprotein immunoprecipitation and luciferase reporter assays validated miRNA roles.
  • Analysis of ENKTL tissues and patient serum samples was conducted.

Main Results:

  • miR-340-5p and miR-424-5p were identified as key regulators of PD-L1 in drug-resistant ENKTL cells.
  • Elevated miR-340-5p in PD-L1-negative ENKTL tissues inversely correlated with soluble PD-L1.
  • Low serum miR-340-5p levels were associated with reduced efficacy of pembrolizumab therapy.

Conclusions:

  • miR-340-5p and miR-424-5p represent potential therapeutic targets in ENKTL.
  • Serum miR-340-5p may serve as a predictive biomarker for pembrolizumab immunotherapy response.
  • Pre-treatment assessment of serum miR-340-5p could guide pembrolizumab therapy decisions in ENKTL.